Cellular vesicles-based "all-in-one" vaccine platform triggers mucosal immunity against respiratory viruses
文献类型：期刊论文
| 作者 | Gao, Yanrong4,5; Zhu, Jie4,5; Zhai, Jimao4,5; Ou, Ante4,5; Fan, Baoru4,5; Wu, Han4,5; Turaev, Abbaskhan3; Muhitdinov, Bahtiyor3; Wang, Huiyuan5 ; Huang, Yongzhuo1,2,4,5
|
| 刊名 | NANO TODAY
 |
| 出版日期 | 2024-12-01 |
| 卷号 | 59页码:12 |
| 关键词 | Inhaled vaccine Cell membrane vesicles Respiratory viruses CpG SARS-CoV-2 |
| ISSN号 | 1748-0132 |
| DOI | 10.1016/j.nantod.2024.102473 |
| 通讯作者 | Wang, Huiyuan(wanghuiyuan@simm.ac.cn) ; Huang, Yongzhuo(yzhuang@simm.ac.cn) |
| 英文摘要 | Viruses transmitted through the respiratory tract tend to have short incubation periods and are highly contagious, thus being one of the main triggers of acute respiratory illnesses. Vaccines are important tools for reducing viral infections and preventing serious illness, hospitalization, and death. However, vaccines are still not widely accessible in some areas, particularly in low-income countries, because of limited production capacity and inadequate medical personnel, resulting in high morbidity and mortality rates during pandemics. Therefore, there is an urgent need for the development of vaccines that can be rapidly manufactured and self-administered in response to pandemics caused by respiratory-transmitted viruses. In this work, we developed an inhalable vaccine platform consisting of antigen-engineered cell membrane vesicles (CMVs) and cholesterolized CpG anchoring to the vesicle surface to establish an "all-in-one" vaccine platform (antigen/CpG-CMVs), which could induce mucosal immunity upon oropharyngeal inhalation to protect against viral infections in the respiratory tract. Its antigen, adjuvant, and particle size can be adjusted as needed through gene editing, cholesterol modification, and extrusion process, respectively. The lyophilized antigen/CpG-CMVs can be distributed without cold-chain transportation and can be self-administered by inhalation upon reconstitution. We found that this inhalable "all-in-one" vaccine induced not only systemic immunity but also mucosal immunity in the respiratory tract, as reflected by the enhanced levels of systemic immunoglobulin G (IgG) and respiratory secreted immunoglobulin A (sIgA). This work may validate engineered cell membrane vesicles as an inhalable vaccine platform and a promising avenue for future vaccine development to protect against pandemics. |
| WOS关键词 | NEUTRALIZATION |
| 资助项目 | Grand Challenges[083GJHZ2023021GC] ; International Partnership Program of the Chinese Academy of Sciences[083GJHZ2023012FN] ; NFSC (China)[81925035] ; NFSC (China)[82341232] ; Chinese Academy of Sciences President's International Fellowship Initiative[2024VBB0004] |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
| 语种 | 英语 |
| WOS记录号 | WOS:001309825200001 |
| 出版者 | ELSEVIER SCI LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/313284]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wang, Huiyuan; Huang, Yongzhuo |
| 作者单位 | 1.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Shanghai 201203, Peoples R China 2.Shanghai Inst Mat Med, Zhongshan Inst Drug Discovery, Zhongshan 528437, Peoples R China 3.Uzbek Acad Sci, AS Sadykov Inst Bioorgan Chem, Tashkent 100125, Uzbekistan 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Gao, Yanrong,Zhu, Jie,Zhai, Jimao,et al. Cellular vesicles-based "all-in-one" vaccine platform triggers mucosal immunity against respiratory viruses[J]. NANO TODAY,2024,59:12. |
| APA | Gao, Yanrong.,Zhu, Jie.,Zhai, Jimao.,Ou, Ante.,Fan, Baoru.,...&Huang, Yongzhuo.(2024).Cellular vesicles-based "all-in-one" vaccine platform triggers mucosal immunity against respiratory viruses.NANO TODAY,59,12. |
| MLA | Gao, Yanrong,et al."Cellular vesicles-based "all-in-one" vaccine platform triggers mucosal immunity against respiratory viruses".NANO TODAY 59(2024):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。